Insider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) Director Sells 1,000 Shares of Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Lantheus Trading Down 0.1 %

Lantheus stock traded down $0.11 during mid-day trading on Friday, reaching $91.47. The company's stock had a trading volume of 585,479 shares, compared to its average volume of 746,461. The business has a 50 day moving average price of $89.64 and a 200-day moving average price of $99.77. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The firm has a market cap of $6.36 billion, a price-to-earnings ratio of 15.22 and a beta of 0.46.

Wall Street Analysts Forecast Growth

Several research firms recently commented on LNTH. The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target on the stock. JMP Securities reiterated a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. Finally, Truist Financial reissued a "buy" rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $131.86.

Institutional Trading of Lantheus

A number of institutional investors and hedge funds have recently made changes to their positions in LNTH. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus in the 3rd quarter worth about $25,000. Signaturefd LLC increased its stake in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 92 shares during the period. Nkcfo LLC bought a new stake in shares of Lantheus during the second quarter valued at approximately $47,000. UMB Bank n.a. boosted its position in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after buying an additional 126 shares during the period. Finally, Kathleen S. Wright Associates Inc. bought a new position in Lantheus in the 3rd quarter worth approximately $51,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.